7 Ovarian Cancer News and Updates That Patients May Have Missed in 2020

A roundup of some ovarian cancer news and updates that occurred in 2020 that patients may have missed.

There were several updates in the field of ovarian cancer in 2020. CURE® looks back at some of the news and updates in the field of ovarian cancer that patients may have missed.

  • The Food and Drug Administration’s (FDA) approval of Zejula (niraparib) in May for the frontline maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy was exciting news for patients, according to a gynecologic oncology expert. READ MORE.
  • Data published in JAMA Oncology demonstrated that regardless of length of breastfeeding, women who breastfeed are at significantly lower risk of ovarian cancer. READ MORE.
  • In an episode of the “CURE Talks Cancer” podcast, we spoke with a cervical cancer survivor — currently living with ovarian cancer — about a cross-country journey she took on a teal and white Harley Davidson motorcycle in the summer of 2019 to raise awareness for ovarian cancer. LISTEN HERE.
  • Data from a case-controlled analysis of health insurance claims from a five-year period demonstrated that certain recurring symptoms appear to be associated with an ovarian cancer diagnosis, indicating that symptom awareness is relevant to identifying a disease that is typically diagnosed at a later stage. READ MORE.
  • Most premenopausal women planning preventive surgery because of a predisposition to ovarian cancer would prefer to remove only their fallopian tubes, putting off removal of their ovaries until they reach menopause, recent study results demonstrated. READ MORE.
  • There was not a statistically significant association between the use of powder in the genital area and risk for ovarian cancer, according to data published in JAMA Network. READ MORE.
  • Treatment with Keytruda (pembrolizumab), Avastin (bevacizumab) and cyclophosphamide in patients with recurrent ovarian cancer was well tolerated and demonstrated clinical benefit in most patients, according to results from a trial published in JAMA Oncology. READ MORE.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.